SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition of Matter patent which covers over 40 potential disease...

SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their...